Petrichor Welcomes Diagnostics Pioneer Don Hardison as New Operating Partner

Petrichor Welcomes Don Hardison as Operating Partner

In a significant move for the healthcare investment landscape, Petrichor, a prominent investor in the healthcare and life sciences sectors, has announced the appointment of Don Hardison as Operating Partner. With an extensive career spanning over four decades in the diagnostics and biotechnology industries, Hardison brings a wealth of knowledge and operational expertise that is expected to enhance Petrichor's ability to invest in and grow innovative healthcare companies.

Tadd Wessel, Managing Partner at Petrichor, expressed his enthusiasm about Hardison's addition to the team, stating, "Don's unmatched operational experience in diagnostics makes him an invaluable addition to Petrichor. His deep understanding of scaling complex businesses and driving operational performance will greatly enhance our ability to partner with innovative companies and management teams to build category-leading healthcare entities."

Don Hardison's Remarkable Career

Hardison's remarkable career includes notable positions such as President and CEO of Exact Sciences, where he played a pivotal role during the company's critical early growth phase and oversaw its initial public offering (IPO). Before that, he held the position of Executive Vice President and Chief Operating Officer at LabCorp, where he was instrumental in optimizing operations and expanding the company's commercial reach.

Most recently, Hardison served as the President and CEO of Biotheranostics, leading the organization to a successful acquisition by Hologic in February 2021. His broad experience also includes serving on numerous boards within the diagnostics and life sciences sectors, equipping him with a comprehensive understanding of industry dynamics and the keys to fostering robust business outcomes.

A Vision for Transformed Patient Care

Expressing his excitement about joining Petrichor, Hardison stated, "I am thrilled to come on board as an Operating Partner and work with such a talented team. Together, we will support companies that are transforming patient care. Petrichor's thoughtful, value-added approach and commitment to driving results resonate with my passion for advancing innovative diagnostics that lead to better health outcomes for patients."

In his new role, Hardison currently chairs the Board of Directors at Geneoscopy, a company within the Petrichor portfolio. Geneoscopy is recognized for its cutting-edge, non-invasive diagnostics with a focus on colorectal cancer. Under Hardison's leadership, Geneoscopy is advancing towards the commercialization of its flagship colorectal cancer screening test while expanding its portfolio of diagnostic solutions.

Petrichor: A Giant in Healthcare Investments

Petrichor stands as a leader in investing in healthcare, having completed over 125 investments that represent more than $6 billion in capital. The firm prides itself on its unique blend of scientific, technical, and commercial expertise, which empowers it to build and scale successful healthcare businesses efficiently. With a robust track record of over 50 board seats held across various healthcare companies, Petrichor is well-positioned to support its portfolio firms in navigating challenges and achieving transformative growth.

As healthcare continues to evolve, the strategic addition of Don Hardison is expected to propel Petrichor's mission to partner with best-in-class healthcare innovators, ultimately leading to improved patient care and positive health outcomes.

For further information on Petrichor and its initiatives, please visit www.petrichorcap.com.